Tirzepatide·Eli Lilly·Injectable pen

Mounjaro

Mounjaro is a once-weekly injectable tirzepatide pen manufactured by Eli Lilly, FDA-approved in May 2022 for the treatment of type 2 diabetes. As the first dual GIP/GLP-1 receptor agonist to reach the market, Mounjaro represents a new class of incretin-based therapy that targets two metabolic pathways simultaneously. In clinical trials, Mounjaro produced unprecedented weight loss results of 15-21% of body weight depending on the dose, surpassing all existing GLP-1 medications. At Weight Method, tirzepatide treatment starts at $349/month with comprehensive provider support and free home delivery.

2.5mg5mg7.5mg10mg12.5mg15mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Mounjaro is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Mounjaro (tirzepatide) is an FDA-approved GLP-1 medication for weight loss. In clinical trials, patients lost an average of 15-22% of their body weight. Weight Method offers Mounjaro starting at $297/month with virtual consultations and direct shipping.

Key Fact

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes in May 2022. SURMOUNT-1 trial showed 22.5% average weight loss at the 15mg dose — the highest of any approved medication in its class.

Source: SURMOUNT-1 Trial — Jastreboff et al., NEJM 2022

How does this medication work?

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist — targeting two metabolic hormones simultaneously to suppress appetite, boost fat metabolism, and improve insulin response.

Mounjaro works through a first-in-class dual-agonist mechanism, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. While GLP-1 activation suppresses appetite and slows gastric emptying -- similar to semaglutide -- the addition of GIP receptor activation enhances fat metabolism, improves how the body processes and stores energy, and amplifies insulin secretion from the pancreas. This two-pronged hormonal approach addresses weight and blood sugar from multiple biological pathways, which is believed to explain why Mounjaro produces greater average weight loss than single-receptor GLP-1 medications like Ozempic or Wegovy.

What is it FDA-approved for?

FDA-approved for type 2 diabetes (2022), widely prescribed off-label for weight loss. Zepbound is the weight-specific brand of the same tirzepatide molecule.

Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. While Mounjaro does not currently carry a formal FDA indication for weight management (that indication belongs to its sister product Zepbound), physicians frequently prescribe Mounjaro off-label for weight loss given its exceptional clinical trial data. The SURPASS trial program demonstrated significant A1C reductions alongside weight loss that exceeded all prior GLP-1 monotherapy results, making Mounjaro a powerful option for patients with type 2 diabetes who also need to lose weight.

What are the key facts you should know?

Once-weekly injection, 2.5mg to 15mg dose range, first-in-class dual agonist, SURMOUNT-1 showed 22.5% weight loss at 15mg, manufactured by Eli Lilly.

Mounjaro is available in six dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, administered once weekly via a pre-filled injectable pen. In the SURMOUNT-1 trial (which studied the same tirzepatide molecule in patients without diabetes), participants on the 15mg dose lost an average of 22.5% of body weight over 72 weeks. Mounjaro was the first medication in its class and remains the only approved dual GIP/GLP-1 agonist for type 2 diabetes. It is manufactured by Eli Lilly at facilities in the United States and has been available since mid-2022.

Why choose this treatment?

Mounjaro's dual-hormone mechanism produces 5-7% greater weight loss than single-receptor GLP-1 drugs, outperforming all comparators in SURPASS and SURMOUNT trials.

Mounjaro may be the right choice if you have type 2 diabetes and want the most aggressive weight loss potential alongside superior blood sugar control. Its dual-receptor mechanism produces approximately 5-7% more weight loss on average compared to semaglutide-based medications, and the SURPASS trials demonstrated it outperformed all comparator diabetes medications on both A1C reduction and weight loss. At Weight Method, tirzepatide treatment starts at $349/month -- dramatically less than the $1,000+/month retail price -- with licensed provider oversight, personalized dosing, and free delivery.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors, while Ozempic contains semaglutide, which activates only GLP-1 receptors. This dual-agonist mechanism gives Mounjaro a distinct pharmacological advantage: in head-to-head comparisons, tirzepatide produced approximately 5-7% greater body weight reduction than semaglutide. Mounjaro is also dosed differently, starting at 2.5mg with a maximum of 15mg.

While Mounjaro is FDA-approved specifically for type 2 diabetes, licensed providers can prescribe it off-label for weight management in eligible patients. Alternatively, Zepbound -- which contains the same tirzepatide molecule -- is FDA-approved specifically for weight loss. Your Weight Method provider will determine which tirzepatide formulation is most appropriate for your situation.

The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These typically occur during the initial weeks and after dose increases, and they generally improve as your body adjusts. The gradual dose-escalation schedule -- starting at 2.5mg and increasing every 4 weeks -- is designed to minimize these effects.

In clinical trials, patients on tirzepatide (the active ingredient in Mounjaro) lost 15-22.5% of body weight depending on the dose and study duration. The SURMOUNT-1 trial showed an average loss of 22.5% at the 15mg dose over 72 weeks. In real-world practice with diabetes patients, weight loss typically ranges from 15-21%. Individual results depend on dose, adherence, and lifestyle factors.

Weight Method offers tirzepatide treatment at $349/month with no insurance required. Brand-name Mounjaro can cost over $1,000/month at retail pharmacies without insurance. Weight Method's transparent pricing includes your medication, licensed provider consultations, personalized dose management, and free home delivery.

Clinical data suggests tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Wegovy/Ozempic) -- approximately 22.5% vs. 15% in comparable trial populations. However, 'better' depends on your individual health profile, goals, and tolerability. Some patients respond exceptionally well to semaglutide. Your Weight Method provider will recommend the medication best suited to your needs.

Most patients notice reduced appetite and early weight loss within the first 2-4 weeks of treatment. Clinically significant weight loss typically becomes visible by weeks 8-12 as the dose escalates. The full effect is generally observed after 6-12 months of consistent use at your maintenance dose. Your Weight Method provider monitors your progress throughout and adjusts your plan accordingly.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Mounjaro

Mounjaro Side EffectsMounjaro ResultsMounjaro Dosingtirzepatide Dosage Calculator

Generic Medication

Tirzepatide

Other Tirzepatide Brands

ZepboundTirzepatide

Compare Mounjaro

Mounjaro vs ZepboundOzempic vs MounjaroWegovy vs Mounjaro

Mounjaro by State

Mounjaro in AlabamaMounjaro in AlaskaMounjaro in ArizonaMounjaro in ArkansasMounjaro in CaliforniaMounjaro in Colorado